Moderna’s Bancel Prepares for Transition Year as Covid Vaccine Sales Wane

Moderna Inc. is looking for potential approval of two new vaccines this year to help compensate for waning sales of its Covid-19 shot, according to Chief Executive Officer Stephane Bancel.

Sales of the Covid vaccine, Spikevax, will be at least $5 billion this year, a figure that could rise as the company signs additional government contracts and starts selling to private companies in the US this year, Bancel said Monday in an interview at the JPMorgan Healthcare Conference in San Francisco. Last year’s sales were about $18.4 billion, the company said in a statement.